The DOI matches its Crossref record.
A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus–associated cryoglobulinemic vasculitis
Open accessAbstract
Objective: To perform a randomized controlled trial of rituximab in patients with hepatitis C virus (HCV)–associated mixed cryoglobulinemic vasculitis. Methods: We conducted a single‐center, open‐label, randomized controlled trial of rituximab (375 mg/ m 2/week for 4 weeks) compared to the best available therapy (maintenance or increase in immunosuppressive therapy) for HCV‐associated cryoglobulinemic vasculitis in patients in whom antiviral therapy had failed to induce remission. The primary end point was disease remission at 6 months from study entry. Results: A total of 24 patients were enrolled (12 in each treatment group). Baseline disease activity and organ involvement were similar in the two groups. Ten patients in the rituximab group (83%) were in remission at study month 6, as compared with 1 patient in the control group (8%), a result that met the criterion for stopping the study (P < 0.001). The median duration of remission for rituximab‐treated patients who reached the primary end point was 7 months. No adverse effects of rituximab on HCV plasma viremia or on hepatic transaminase levels were observed. Conclusion: Rituximab was a well‐tolerated and effective treatment in patients with HCV‐associated cryoglobulinemic vasculitis in whom antiviral therapy failed to induce remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Schwartz, J., Padmanabhan, A., Aqui, N., Balogun, R. A., Connelly‐Smith, L., Delaney, M., Dunbar, N. M., Witt, V., Wu, Y., & Shaz, B. H. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21470 · Cited by 793
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Schwartz, J., Winters, J. L., Padmanabhan, A., Balogun, R. A., Delaney, M., Linenberger, M. L., Szczepiorkowski, Z. M., Williams, M. E., Wu, Y., & Shaz, B. H. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21276 · Cited by 603
Extrahepatic manifestations of chronic hepatitis C virus infection
Cacoub, P., Gragnani, L., Comarmond, C., & Zignego, A. L. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.10.005 · Cited by 293
Extrahepatic manifestations of chronic hepatitis C virus infection
Cacoub, P., Comarmond, C., Domont, F., Savey, L., Desbois, A. C., & Saadoun, D. (2016) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936115585942 · Cited by 291
Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct‐acting antiviral agents
Sise, M. E., Bloom, A. K., Wisocky, J., Lin, M. V., Gustafson, J. L., Lundquist, A. L., Steele, D., Thiim, M., Williams, W. W., Hashemi, N., et al. (2016) · Hepatology · doi:10.1002/hep.28297 · Cited by 261
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Muchtar, E., Magen, H., & Gertz, M. A. (2017) · Blood · doi:10.1182/blood-2016-09-719773 · Cited by 190
Metadata
- Authors
- Sneller, M. C., Hu, Z., & Langford, C. A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-02-28
- Volume
- 64
- Issue
- 3
- Pages
- 835-842
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2117786286
- Cited by
- 236
- References
- 0
- FWCI
- 14.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.